ARKG vs SPXU

ARK Genomic Revolution ETF vs ProShares UltraPro Short S&P500

Quick take
  • ARKG has the lower expense ratio at 0.75% vs 0.90% for SPXU.
  • SPXU pays a higher dividend yield (6.85%).

Side-by-side metrics

MetricARKGSPXU
Expense ratio
Annual fee. Lower is better.
0.75%0.90%
Dividend yield
Trailing 12-month yield.
0.00%6.85%
AUM
Assets under management — bigger funds are typically more liquid.
$1.73B$427M
YTD return
44.53%-23.50%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.38-2.75
P/E ratio
Last price
$43.00$36.42
Inception
Issuer
ARKProShares

ARKG top holdings

Top holdings · ARKG
TWSTTwist Bioscience Corp9.15%
TEMTempus AI Inc Class A common stock7.64%
ABSIAbsci Corp7.01%
TXG10x Genomics Inc Ordinary Shares - Class A7.00%
CRSPCRISPR Therapeutics AG6.56%
PSNLPersonalis Inc6.19%
BEAMBeam Therapeutics Inc4.34%
GHGuardant Health Inc4.28%
NTRANatera Inc4.11%
ILMNIllumina Inc3.98%
Sector breakdown · ARKG
Healthcare100.0%

SPXU top holdings

Top holdings · SPXU
IQMMProShares GENIUS Money Market ETF78.53%

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About SPXU

SPXU (ProShares UltraPro Short S&P500) is 3x inverse daily performance of the S&P 500. Managed by ProShares, the fund carries $427M in assets under management, an expense ratio of 0.90%, a dividend yield of 6.85%. Its largest holding is ProShares GENIUS Money Market ETF (IQMM), which represents 78.5% of the portfolio.